• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Advances in Pseudoprogression of Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].[免疫检查点抑制剂在非小细胞肺癌中假性进展的研究进展]
Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):306-320. doi: 10.3779/j.issn.1009-3419.2024.101.10.
2
[Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].[接受免疫治疗的晚期非小细胞肺癌患者超进展性疾病的研究进展]
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):271-278. doi: 10.3779/j.issn.1009-3419.2021.101.08.
3
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.体素内不相干运动磁共振成像预测非小细胞肺癌患者免疫检查点抑制剂的长期疗效。
Lung Cancer. 2020 May;143:47-54. doi: 10.1016/j.lungcan.2020.03.013. Epub 2020 Mar 18.
4
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
5
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.皮质类固醇对免疫检查点抑制剂治疗晚期非小细胞肺癌患者结局的影响。
Eur J Cancer. 2021 Mar;145:245-254. doi: 10.1016/j.ejca.2020.12.012. Epub 2021 Jan 5.
6
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.国家免疫治疗登记处人群水平晚期非小细胞肺癌的检查点抑制剂的疗效。
Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28.
7
Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.免疫检查点抑制剂在 80 岁或以上的非小细胞肺癌患者中的疗效和安全性。
Cancer Rep (Hoboken). 2021 Dec;4(6):e1405. doi: 10.1002/cnr2.1405. Epub 2021 May 2.
8
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).二线或以上免疫检查点抑制剂治疗下快速进展的非小细胞肺癌患者的管理和结局：ERORECI 研究（GFPC 2016-04）。
Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20.
9
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌：合理选择。
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
10
The cutting-edge progress of immune-checkpoint blockade in lung cancer.免疫检查点阻断在肺癌中的最新进展。
Cell Mol Immunol. 2021 Feb;18(2):279-293. doi: 10.1038/s41423-020-00577-5. Epub 2020 Nov 11.

本文引用的文献

1
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.不同实体瘤接受免疫检查点抑制剂治疗后的假性进展模式。
Cancer Imaging. 2023 Jun 8;23(1):58. doi: 10.1186/s40644-023-00580-9.
2
Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.肿瘤初治循环肿瘤 DNA 作为早期临床试验中接受免疫治疗患者的早期反应生物标志物。
JCO Precis Oncol. 2023 Apr;7:e2200509. doi: 10.1200/PO.22.00509.
3
Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report.纳武利尤单抗联合伊匹木单抗与化疗用于转移性肺腺癌诱导治疗期间的假性进展：一例报告
Respirol Case Rep. 2023 Mar 13;11(4):e01122. doi: 10.1002/rcr2.1122. eCollection 2023 Apr.
4
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.KEYNOTE-042 研究中，PD-L1 肿瘤比例分数≥1%的非小细胞肺癌患者中，帕博利珠单抗对比化疗作为一线治疗的 5 年总生存期结果。
J Clin Oncol. 2023 Apr 10;41(11):1986-1991. doi: 10.1200/JCO.21.02885. Epub 2022 Oct 28.
5
Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.联合化疗免疫治疗后晚期非小细胞肺癌的假性进展：一例报告。
J Med Case Rep. 2022 Jul 25;16(1):289. doi: 10.1186/s13256-022-03485-6.
6
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.用于评估肺癌患者免疫治疗反应的氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描（FDG PET/CT）
Semin Nucl Med. 2022 Nov;52(6):707-719. doi: 10.1053/j.semnuclmed.2022.04.010. Epub 2022 May 27.
7
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.个性化循环肿瘤DNA分析作为帕博利珠单抗治疗实体瘤患者的预测生物标志物
Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3.
8
Disease progression and pseudoprogression following partial response with rare gingiva metastasis upon IBI308 (sintilimab) immunotherapy reflects the complexity of metastatic lung cancer: a case report.IBI308（信迪利单抗）免疫治疗后出现部分缓解并伴有罕见牙龈转移的疾病进展和假性进展反映了转移性肺癌的复杂性：一例报告
Transl Cancer Res. 2021 Jan;10(1):546-552. doi: 10.21037/tcr-20-2736.
9
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.PACIFIC试验的五年生存结果：III期非小细胞肺癌放化疗后使用度伐利尤单抗治疗
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
10
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics.使用Delta放射组学探索非小细胞肺癌对免疫治疗的反应
Cancers (Basel). 2022 Jan 11;14(2):350. doi: 10.3390/cancers14020350.

[免疫检查点抑制剂在非小细胞肺癌中假性进展的研究进展]

[Advances in Pseudoprogression of Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].

作者信息

Tong Yajun, Long Yong, Zhang Fan, Li Junfeng

机构信息

Department of Oncology, Yueyang Central Hospital, Yueyang 414000, China.

Department of Oncology, Xiangya Changde Hospital, Changde 415000, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):306-320. doi: 10.3779/j.issn.1009-3419.2024.101.10.

DOI:10.3779/j.issn.1009-3419.2024.101.10
PMID:38769834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11110244/
Abstract

The advent of immune checkpoint inhibitors (ICIs) has greatly improved the prognosis of advanced lung cancer patients, but can lead to pseudoprogression (PsP), which complicates clinical evaluation and management. PsP is manifested as temporary enlargement of the tumour or the appearance of new lesions, etc., and improvement in imaging occurs with continued treatment, mostly without worsening of clinical symptoms. Currently, there are still difficulties in the early diagnosis of PsP, and its occurrence mechanism is not yet clear, lacking good predictive factors and related biomarkers. This article reviews the current research status of PsP of ICIs in non-small cell lung cancer in order to provide helpful clinical strategies for oncologists using these drugs.
.

摘要

免疫检查点抑制剂（ICI）的出现极大地改善了晚期肺癌患者的预后，但可能导致假性进展（PsP），这使临床评估和管理变得复杂。PsP表现为肿瘤暂时增大或出现新病灶等，持续治疗后影像学表现改善，多数患者临床症状无恶化。目前，PsP的早期诊断仍存在困难，其发生机制尚不清楚，缺乏良好的预测因素和相关生物标志物。本文综述了ICI在非小细胞肺癌中PsP的研究现状，旨在为使用这些药物的肿瘤学家提供有益的临床策略。